Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetic peripheral neuropathies.

Y Harati

    Annals of Internal Medicine
    |October 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Diabetic peripheral neuropathies affect over 50% of diabetes patients, with vascular factors and hyperglycemia playing roles. Current treatments focus on blood glucose control, as other therapies lack proven safety and efficacy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diabetic peripheral neuropathies.

    Methodist DeBakey cardiovascular journal·2010
    Same author

    What's in the Literature?

    Journal of clinical neuromuscular disease·2009
    Same author

    Neuromuscular highlights from the american academy of neurology annual meeting.

    Journal of clinical neuromuscular disease·2008
    Same author

    Occurrence of amyotrophic lateral sclerosis among Gulf War veterans.

    Neurology·2003
    Same author

    Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology.

    Neurology·2001
    Same author

    Motor unit number estimation, ALS and clinical trials.

    Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2001
    Same journal

    Correction to I.M. Matters News: Sleep medicine for seniors.

    Annals of internal medicine·2026
    Same journal

    Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

    Annals of internal medicine·2026
    Same journal

    Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

    Annals of internal medicine·2026
    Same journal

    Grappling with GLP-1 prescribing.

    Annals of internal medicine·2026
    See all related articles

    Area of Science:

    • Neurology
    • Endocrinology
    • Vascular Biology

    Background:

    • Diabetic peripheral neuropathies are common, heterogeneous syndromes causing significant morbidity.
    • Over 50% of diabetic patients develop neuropathies within 25 years of diagnosis.
    • Emerging research links various pathogenetic mechanisms, including vascular factors via the hypoxic hypothesis.

    Purpose of the Study:

    • To review the pathogenesis of diabetic peripheral neuropathies.
    • To evaluate the role of hyperglycemia and vascular factors.
    • To assess current and proposed treatment strategies.

    Main Methods:

    • Literature review of pathogenetic mechanisms.
    • Analysis of evidence linking hyperglycemia and vascular factors.

    Related Experiment Videos

  • Evaluation of treatment efficacy and safety data.

    • Main Results:

    • Hyperglycemia's exact role is unclear, but blood glucose control is crucial.
    • Vascular factors, particularly hypoxia, are increasingly implicated.
    • No alternative treatments show sufficient value or safety for routine use.

    Conclusions:

    • Maintaining normal blood glucose is the primary treatment for diabetic neuropathies.
    • Further research is needed to clarify pathogenesis and develop effective treatments.
    • Current evidence does not support routine use of therapies targeting metabolic derangements in nerves.